Moviprep is a drug owned by Salix Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 01, 2024. Details of Moviprep's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7169381 | Colon cleansing compositions and methods |
Sep, 2024
(10 months ago) |
Expired
|
| US7658914 | Colon cleansing compositions |
Sep, 2024
(10 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Moviprep's patents.
Latest Legal Activities on Moviprep's Patents
Given below is the list of recent legal activities going on the following patents of Moviprep.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Jul, 2021 | US7658914 |
| Change in Power of Attorney (May Include Associate POA) Critical | 15 Oct, 2020 | US7658914 |
| Email Notification Critical | 15 Oct, 2020 | US7658914 |
| Correspondence Address Change Critical | 13 Oct, 2020 | US7658914 |
| Email Notification Critical | 29 Sep, 2020 | US7169381 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 Sep, 2020 | US7169381 (Litigated) |
| Correspondence Address Change Critical | 27 Sep, 2020 | US7169381 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jul, 2018 | US7169381 (Litigated) |
| Post Issue Communication - Certificate of Correction | 11 Apr, 2010 | US7658914 |
| Post Issue Communication - Certificate of Correction | 18 Mar, 2010 | US7658914 |
Several oppositions have been filed on Moviprep's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Moviprep's generic, the next section provides detailed information on ongoing and past EP oppositions related to Moviprep patents.
Moviprep's Oppositions Filed in EPO
Moviprep has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 12, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP03758361A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP03758361A | May, 2009 | Teva Pharmaceutical Industries LTD. | Opposition procedure closed |
US patents provide insights into the exclusivity only within the United States, but Moviprep is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Moviprep's family patents as well as insights into ongoing legal events on those patents.
Moviprep's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Moviprep's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 01, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Moviprep Generic API suppliers:
Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate is the generic name for the brand Moviprep. 2 different companies have already filed for the generic of Moviprep, with Novel Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Moviprep's generic
How can I launch a generic of Moviprep before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Moviprep's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Moviprep's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Moviprep -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch | 27 Nov, 2007 | 1 | 25 Jan, 2012 | 01 Sep, 2024 | Eligible |
Alternative Brands for Moviprep
There are several other brand drugs using the same active ingredient (Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate) as Moviprep. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Salix |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate, Moviprep's active ingredient. Check the complete list of approved generic manufacturers for Moviprep
About Moviprep
Moviprep is a drug owned by Salix Pharmaceuticals Inc. Moviprep uses Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate as an active ingredient. Moviprep was launched by Salix Pharms in 2006.
Approval Date:
Moviprep was approved by FDA for market use on 02 August, 2006.
Active Ingredient:
Moviprep uses Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate as the active ingredient. Check out other Drugs and Companies using Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate ingredient
Dosage:
Moviprep is available in for solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM | FOR SOLUTION | Prescription | ORAL |